About: Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19
Creator	Ikeda, Mayu Imai, Kazuo Ito, Toshimitsu Kitagawa, Yutaro Maeda, Takuya Maesaki, Shigefumi Matuoka, Masaru Miyoshi, Kazuyasu Noguchi, Sakiko Sakai, Jun Tabata, Sakiko Tamura, Kaku Tarumoto, Norihito
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19). METHODS: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission. FINDINGS: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1–2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively. CONCLUSION: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19.
has issue date	2020-04-30(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104393
bibo:pmid	32387968
has license	no-cc
sha1sum (hex)	165c4581ff3772a22d772f0cc5c38dda8a21bcc2
schema:url	https://doi.org/10.1016/j.jcv.2020.104393
resource representing a document's title	Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19
has PubMed Central identifier	PMC7191278
has PubMed identifier	32387968
schema:publication	J Clin Virol
resource representing a document's body	covid:165c4581ff3772a22d772f0cc5c38dda8a21bcc2#body_text
is schema:about of	named entity 'diagnosis' named entity 'computed tomography' named entity 'IgG' named entity 'determined' named entity 'Antibody' named entity 'chest' named entity 'asymptomatic' named entity 'chest' named entity 'computed tomography' named entity 'IgM' named entity 'performance' named entity 'patients' named entity 'IgM' named entity 'IgM' named entity 'week' named entity 'asymptomatic' named entity 'patients' named entity 'detected' named entity 'IgG' named entity 'weeks' named entity 'IgG' named entity 'collected' named entity 'IgM' named entity 'SARS-CoV2' named entity 'IgG antibody' named entity 'symptom' named entity 'IgM' named entity 'IgM' named entity 'assay' named entity 'COVID' named entity 'immunochromatographic' named entity 'IgG antibody' named entity 'Coronavirus disease 2019' named entity 'serum' named entity 'SARS' named entity 'computed tomography' named entity 'positive' named entity 'onset' named entity 'chest CT' named entity 'clinical setting' named entity 'COVID' named entity 'SARS-CoV2' named entity 'COVID' named entity 'pharyngeal' named entity 'seroprevalence' named entity 'IgM' named entity 'IgG' named entity 'radiologist' named entity 'SARS-CoV2' named entity 'IgG antibodies' named entity 'COVID-19' named entity 'IgM antibody' named entity 'incubation' named entity 'IgG antibody' named entity 'symptom' named entity 'chest CT' named entity 'tested positive' named entity 'CT scan' named entity 'chest CT' named entity 'IgG antibody' named entity 'Lung' named entity 'pneumonia' named entity '13.0' named entity 'computed tomography' named entity 'IgM' named entity 'COVID-19' named entity 'chest CT' named entity 'SARS-CoV2' named entity 'IgM'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software